Relapsed/Refractory Metastatic NSCLC Tumors Respond to Datopotamab Deruxtecan in Early Trial

A phase 1 trial exploring the investigational antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd; DS-1062) showed the agent’s ability to induce antitumor activity as well as produce an acceptable safety profile in patients with previously treated advanced or metastatic non–small cell lung cancer (NSCLC), results of which were presented at the 2020 World Conference on Lung Cancer (WCLC) Singapore.¹

Preliminary efficacy data from the TROPION-PanTumor01 trial (NCT03401385) showed that datopotamab deruxtecan elicited an overall response rate of 23% (n = 9) at a dose of 4 mg/kg (n = 40), 21% (n = 8) at 6 mg/kg (n = 39), and 25% (n = 20) at 8 mg/kg (n = 80) per blinded independent central review. Confirmed complete or partial responses were observed in 7, 6, and 19 patients, respectively.

Additionally, 2 patients who received the 4 mg/kg dose, 2 patients who received the 6 mg/kg dose, and 1 patient who received the 8 mg/kg dose had suspected complete or partial responses, but longer follow-up is needed to confirm.

The preliminary median progression-free survival was 4.3 months with the 4 mg/kg dose, 8.2 months with the 6 mg/kg dose, and 5.4 months with the 8 mg/kg dose.

Based on these findings, the 6 mg/kg dose of datopotamab deruxtecan was identified as the recommended dose for the registrational, randomized phase 3 TROPION-Lung01 trial (NCT04656652), which is evaluating datopotamab deruxtecan versus docetaxel in patients with previously treated advanced or metastatic NSCLC who do not harbor actionable genomic alterations.²

“Datopotamab deruxtecan showed impressive response rates in a heavily pretreated population,” said Alexander Spira, MD, PhD, FACP, lead study author and director of the Virginia Cancer Specialists Research Institute and phase I trial program, in a statement to CancerNetwork^®. “Toxicity at the recommended phase 2 dose of 6 mg/kg appears to be very reasonable and is being used in the randomized phase 3 study versus docetaxel. The hope is not only to look at this [drug] in later lines, but also look to combine it with other agents, such as immunotherapy and potentially chemotherapy, in the future.”

The open-label TROPION-PanTumor01 trial marks the first-in-human study of datopotamab deruxtecan, a Trop-2–directed ADC, in patients with advanced solid tumors. Trop-2 is a transmembrane glycoprotein that is expressed in many cancers, including lung cancer. Moreover, Trop-2 overexpression is associated with poor outcome.

The ADC is comprised of a topoisomerase 1 inhibitor payload (exatecan derivative), a tetrapeptide-based linker, and a humanized Trop-2–directed monoclonal antibody.

Eligible patients had to have relapsed/refractory advanced or metastatic NSCLC that was unselected for Trop-2 expression. Japanese patients had to be 20 years or older, and patients from the United States had to be 18 years or older to be eligible for enrollment. Additionally, patients had to have an ECOG performance status of 0 or 1, and measurable disease per RECIST v1.1 criteria.

Patients with stable, treated brain metastases were eligible for enrollment.

The majority of patients evaluated in all 3 cohorts had received 3 or more prior lines of therapy, including platinum-based chemotherapy (median 94%), immunotherapy (median 83%), and TKIs (median 17%). A median of 37% of patients across the 3 dosing arms had a history of brain metastases and a median of 14% harbored EGFR mutations.

The median duration of follow-up was 7.4 months; a median of 42% of patients remained on datopotamab deruxtecan at the time of the data cutoff. Additionally, 46% of patients in the 4 mg/kg cohort, 51% of patients in the 6 mg/kg cohort, and 76% of patients in the 8 mg/kg cohort discontinued from study treatment because of progression or adverse effects (AEs).

Additional data showed that 15% (n = 6) of patients in the 4 mg/kg group, 21% (n = 8) of patients in the 6 mg/kg group, and 9% (n = 7) of patients in the 8 mg/kg group experienced progressive disease. Datopotamab deruxtecan induced a disease control rate of 73% (n = 29) with 4 mg/kg, 67% (n = 26) with 6 mg/kg, and 80% (n = 64) with 8 mg/kg.

The pharmacokinetic profile of datopotamab deruxtecan remained consistent throughout 3 cycles of treatment, irrespective of the dose. Moreover, the half-life of the agent was 4.6 days for the 6 mg/kg dose, supporting the every 3-week dosing schedule.

Regarding safety, the toxicity profile observed with datopotamab deruxtecan was consistent with previously reported findings. Notably, grade 3 or higher treatment-emergent AEs were observed in 10% of patients in the 4 mg/kg cohort, 16% of patients in the 6 mg/kg cohort, and 34% of patients in the 8 mg/kg cohort. Serious treatment-related TEAEs occurred in 8%, 9%, and 20% of patients, respectively.

Common grade 3 or greater TEAEs included nausea, stomatitis, fatigue, vomiting, decreased appetite, constipation, infusion-related reactions, mucosal inflammation, anemia, and cough. Overall, patients who received the 8 mg/kg dose had higher rates of these TEAEs compared with those who received the 4 mg/kg or 6 mg/kg doses.

Notably, 8% (n = 14) of patients experienced interstitial lung disease (ILD) as determined by an independent adjudication committee. One grade 3 ILD event was observed with the 4 mg/kg dose of datopotamab deruxtecan, and 1 grade 2 ILD event was observed with the 6 mg/kg dose. The remainder of ILD events occurred in the 8 mg/kg cohort, 3 of which were grade 5.

References:

1. Spira A, Lisberg AE, Sands JM, et al. Datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 ASC, in patients with advanced NSCLC: updated results of TROPION-PanTumor01 phase 1 study. Presented at: International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer; January 28-31, 2021; virtual. Abstract OA03.03.

2. Study of DS-1062A versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer without actionable genomic alterations (TROPION-LUNG01). ClinicalTrials.gov. Posted December 7, 2020. http://bit.ly/39wSgRf.